跳至主要内容
临床试验/NCT00534547
NCT00534547撤回不适用

Phase IV Study of Duodenal Exclusion for the Treatment of Type 2 Diabetes (T2DM)

Medtronic - MITG0 个研究点开始时间: 2007年9月26日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
Treatment success based on patients' glycemic control

研究概览

简要总结

The purpose of this study is to investigate the role of an experimental surgery that may offer better short and long-term control of T2DM in select patients who have not achieved adequate blood sugar control with regular means.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age between 20 and 50 years old;
  • •BMI between 27 and 34.9;
  • •Oral agents or insulin to control T2DM;
  • •Inadequate control of diabetes as defined as HbA1c>8.0% but <10%
  • •Understanding of the mechanisms of action of the treatment

排除标准

  • •More than 5 years of T2DM diagnosis;
  • •C-peptide <1pg/ml (off insulin)
  • •Previous abdominal operations;
  • •History of gastritis
  • •History of GERD
  • •History of peptic ulcer disease
  • •Inflammatory bowel disease
  • •Coagulopathy;
  • •Liver cirrhosis;
  • •Unable to comply with study requirements, follow-up schedule or give valid informed consent;
  • •Currently pregnant (pregnancy test required for confirmation for those of child bearing years)
  • •Patient is not available for programmed follow-up during the study period
  • •Patient is unwilling to forgo good samaritan blood donation during the study period

结局指标

主要结局

Treatment success based on patients' glycemic control

时间窗: 12 Months

次要结局

  • Physiologic Measurements, Comorbidity improvement, Improvement in QOL(12 Months)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验